Dr Hanspeter Gerber | SVP & CSO
3T Biosciences

Dr Hanspeter Gerber, SVP & CSO, 3T Biosciences

Hans-Peter has over 20 years of research and development experience in oncology, including antibody-drug conjugates (ADCs), redirected T-cell targeting compounds and adoptive T-cell therapies. He has been leading Pfizer’s Bioconjugates division as CSO, overseeing Pfizer’ s efforts in ADC sand, redirected T-cell targeting and nanoparticle development. He previously held senior leadership positions at Seattle Genetics and Genentech. Hans-Peter is currently CSO and Senior Vice President at 3T Biosciences, where he is overseeing platform- and therapeutic program development of TCR-T and vaccine therapeutics. He is a recognized leader in oncology drug development,  spanning from target identification and validation, development of novel therapeutic modalities and companion diagnostics, regulatory filings and translational support for early clinical development. He has a proven track record in making initial contacts and to successfully execute external collaborations and licensing deals with academia and corporate partners. 

Hans-Peter is an internationally recognized leader in Oncology drug discovery and development, with a strong record of accomplishments in the field of targeted therapeutics. His work has led to more than eight IND filings for ADCs and bi-specifics, and contributions to BLA submissions of therapeutic antibodies (Avastin) and two ADCs (Mylotarg, Besponsa) in Oncology. He is an author on over 100 peer-reviewed published papers and inventor on over 15 patents in the field of Oncology drug discovery. Dr. Gerber is also a member of the board at NBE Therapeutics, an early stage ADC company located in Basel, Switzerland, developing ADCs with a unique and novel mechanism of action. Hans-Peter Gerber received an MS in Biochemistry and a PhD in Molecular Biology from the University of Zurich, Switzerland.

back to speakers

Sign Up for Event Updates

Contact us

To sponsor or exhibit contact:
Oliver Breed
+44 (0)207 092 1156

oliver.breed@terrapinn.com


To speak:
Lauren Sheppard
+44 (0)207 092 1211

lauren.sheppard@terrapinn.com